Loading...
Loading...
Below are the top drugs-generic stocks on the NASDAQ in terms of return on equity.
The trailing-twelve-month return on equity at Adamas Pharmaceuticals
ADMS is 333.80%. Adamas Pharma's revenue for the same period is $71.10 million.
The trailing-twelve-month return on equity at Versartis
VSAR is 142.80%. Versartis' current ratio is 3.60.
The trailing-twelve-month return on equity at NephroGenex
NRX is 113.30%. NephroGenex's market capitalization is $50.18 million.
The trailing-twelve-month return on equity at Aquinox Pharmaceuticals
AQXP is 60.90%. Aquinox Pharma's EPS for the same period is -$1.57.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in